Home  /  Resource Library  /  Rituximab biosimilar RTXM83 versus reference rituximab in combination with CHOP as first-line treatment for diffuse large B-cell lymphoma: a randomized, double-blind study

Rituximab biosimilar RTXM83 versus reference rituximab in combination with CHOP as first-line treatment for diffuse large B-cell lymphoma: a randomized, double-blind study

Study examined the effectiveness of rituximab biosimilar RTXM83 for treatment of B-cell non-Hodgkin lymphoma.